Buy Generic Sofosbuvir Online

Generic Sofosbuvir Information

Introduction

Sofosbuvir is an oral antiviral agent used primarily for the treatment of chronic hepatitis C virus (HCV) infection. In Hong Kong, HCV remains a public‑health concern, with an estimated prevalence of .5 % among adults and a growing need for highly effective, well‑tolerated therapies. Sofosbuvir belongs to the direct‑acting antiviral (DAA) class and targets the viral RNA‑dependent RNA polymerase, a key enzyme in HCV replication. The drug is marketed globally under several brand names, most notably Sovaldi® (Gilead Sciences).

What is Sofosbuvir?

Sofosbuvir is the generic version of Sovaldi®, containing the same active compound, Sofosbuvir. It was originally discovered and developed by Pharmasset, later acquired by Gilead Sciences, and received first regulatory approval in the United States in 2013. The medication is classified as a nucleotide‑analogue NS5B polymerase inhibitor and is listed in the World Health Organization’s Model List of Essential Medicines for HCV.

Sofosbuvir is supplied as film‑coated tablets containing 400 mg of the active ingredient. Our online pharmacy provides this generic alternative as a cost‑effective treatment option for adults in Hong Kong who require HCV therapy.

How Sofosbuvir Works

Sofosbuvir is a prodrug that is metabolised intracellularly to the active triphosphate form, GS‑7334. This active metabolite mimics the natural substrate of the HCV NS5B RNA‑dependent RNA polymerase. When incorporated into the nascent viral RNA chain, it acts as a chain terminator, halting elongation and thereby preventing replication of the virus.

Key pharmacologic points:

• Rapid intracellular activation: Conversion to the triphosphate occurs within hours after oral ingestion.
• High barrier to resistance: The binding site of NS5B is highly conserved, limiting the emergence of resistant viral strains.
• Long intracellular half‑life: The active triphosphate persists for several days, supporting once‑daily dosing.
• Predominant hepatic clearance: Approximately 80 % of the administered dose is eliminated via the liver, with minimal renal excretion of unchanged drug.

These properties translate into a swift decline in viral load, oftenetectable HCV RNA by week 4 of therapy in clinical trials.

Conditions Treated with Sofosbuvir

Sofosbuvir is approved—either as monotherapy or in fixed‑dose combination regimens—for the following HCV genotypes and clinical scenarios:

• Genotype 1 (subtype 1a, 1b): Used in combination with ledipasvir, velpatasvir, or ribavirin plus interferon‑free regimens.
• Genotype 2 and 3: Often combined with ribavirin; velpatasvir‑based regimens provide pan‑genotypic coverage.
• Genotype 4, 5, 6: Pan‑genotypic combinations (e.g., sofosbuvir/velpatasvir) are approved.
• Patients with compensated cirrhosis: Sofosbuvir‑based regimens remain effective, though treatment duration may be extended.
• Post‑liver transplant recipients: Approved for use after transplantation to prevent recurrence of HCV infection.

In Hong Kong, genotype distribution is diverse, with genotype 3 contributing a substantial proportion of cases. Sofosbuvir’s pan‑genotypic efficacy makes it a cornerstone of the region’s HCV elimination strategy.

Who is Sofosbuvir For?

Sofosbuvir‑containing regimens are suitable for adult patients who meet the following criteria:

• Chronic HCV infection confirmed by detectable HCV RNA.
• Any HCV genotype, provided the appropriate companion drug is selected.
• Compensated liver disease (Child‑Pugh class A).
• Patients who have failed prior interferon‑based therapy or who are treatment‑naïve.

Situations where Sofosbuvir may be less appropriate:

• Severe renal impairment (eGFR < 30 mL/min/1.73 m²): Sofosbuvir accumulation can increase toxicity; dose adjustment is not recommended.
• Decompensated cirrhosis (Child‑Pugh class B or C): Alternative regimens with specific dosing adjustments are preferred.
• Concurrent use of strong inducers of CYP3A4 or P‑gp (e.g., rifampin, carbamazepine) without appropriate monitoring, as they may reduce drug exposure.

Clinical decision‑making should always incorporate a full medical assessment, including liver fibrosis staging, renal function, and potential drug‑drug interactions.

Risks, Side Effects, and Interactions

Common

• Fatigue
• Headache
• Nausea
• Insomnia

Rare

• Anemia (especially when combined with ribavirin)
• Rash or mild dermatitis
• Elevated liver enzymes (ALT/AST)

Serious

• Severe hepatotoxicity (rare, usually in patients with advanced liver disease)
• Cardiac arrhythmias (limited reports, primarily in patients with pre‑existing conditions)
• Life‑threatening hypersensitivity reactions (e.g., Stevens‑Johnson syndrome)

Drug–Drug Interactions

• Strong inducers of P‑gp (e.g., rifampin, St. John’s wort): Reduce Sofosbuvir plasma concentrations; avoid co‑administration.
• Amiodarone: May increase risk of symptomatic bradycardia; monitor heart rate closely if co‑prescribed.
• HIV protease inhibitors (e.g., ritonavir): No clinically significant interaction, but caution is advised when combined with other DAAs.
• Antacids containing aluminum or magnesium: Do not affect absorption; can be taken concurrently.

Patients should disclose all prescription, over‑the‑counter, and herbal products to their healthcare provider before initiating therapy.

Practical Use: Dosing, Missed Dose, Overdose

• Standard dose: 400 mg Sofosbuvir tablet taken orally once daily, with or without food.
• Combination regimens: Dosing schedules vary (e.g., Sofosbuvir/Velpatasvir 400 mg/100 mg once daily). Follow the specific product label.
• Missed dose: Take the missed tablet as soon as remembered on the same day, but do not double‑dose the next day.
• Overdose: In the event of ingestion of more than the prescribed amount, seek immediate medical attention. Current data suggest low acute toxicity, but monitoring of liver function and renal parameters is recommended.
• Precautions:
  • Alcohol consumption may exacerbate liver injury; limit intake.
  • Use caution in patients with moderate to severe renal impairment; assess eGFR before starting.
  • No dose adjustment is required for age or body weight in adults.

Buying Sofosbuvir from Our Online Pharmacy

Patients in Hong Kong can purchase Sofosbuvir through our online pharmacy. Our service offers several advantages:

• Affordable pricing: We source the generic product at near‑manufacturer cost, providing a substantial saving compared with brand‑name pricing.
• Verified quality: All batches are supplied by licensed overseas manufacturers that meet international Good Manufacturing Practice (GMP) standards.
• Guaranteed delivery: Discreet packaging with express delivery (typically within 7 days) or regular airmail (approximately 3 weeks).
• Online‑only access: Our pharmacy broker service works with accredited overseas pharmacies, enabling patients to obtain medicines that may not be readily available locally.
• Privacy‑focused handling: Orders are processed with strict confidentiality, respecting patient anonymity throughout the transaction.

Our platform is designed for adults seeking a reliable, cost‑effective way to obtain Sofosbuvir when conventional channels are limited.

FAQ

• Is Sofosbuvir approved for use in patients with hepatitis B co‑infection?
  Sofosbuvir is not indicated for hepatitis B treatment. Patients with HBV/HCV co‑infection should be evaluated for antiviral therapy targeting both viruses, as suppressing HCV may lead to HBV reactivation.

• Can Sofosbuvir tablets be crushed or split for easier swallowing?
  The tablets are film‑coated and should be taken whole. Crushing or splitting may affect drug stability and absorption, potentially reducing efficacy.

• What is the typical shelf life of Sofosbuvir tablets when stored at room temperature?
  Manufacturers assign a shelf life of 24 months from the date of manufacture, provided the product is stored at 15‑30 °C, protected from moisture and direct sunlight.

• Does Sofosbuvir special storage conditions during travel?
  No refrigeration is needed. Keep the medication in its original container, away from excessive heat (e.g., in a car trunk) and humidity.

• Are there regional differences in the inactive ingredients of Sofosbuvir tablets?
  Yes. Some markets use lactose as a filler, while others may employ mannitol or cellulose. Patients with specific excipient allergies should verify the exact composition with the supplier.

• How does Sofosbuvir’s efficacy compare with older interferon‑based regimens?
  Clinical trials consistently show SVR (sustained virologic response) rates >95 % with Sofosbuvir‑based DAA regimens, versus 40‑60 % with interferon‑based therapy, and with markedly fewer adverse events.

• Can Sofosbuvir be used in patients undergoing chemotherapy?
  Limited data exist. Because Sofosbuvir is primarily metabolised in the liver and has a low potential for drug‑enzyme induction, it may be co‑administered, but careful monitoring of liver function and drug interactions is essential.

• Is there any impact of Sofosbuvir on standard drug‑testing panels (e.g., workplace testing)?
  Sofosbuvir and its metabolites are not screened for in routine occupational drug‑testing programs and are unlikely to cause false‑positive results.

• What are the regulatory requirements for personally importing Sofosbuvir into Hong Kong?
  Individuals may import a 30‑day supply for personal use under Hong Kong’s import exemption, provided a valid prescription from a licensed practitioner is retained for customs inspection.

• Does Sofosbuvir have any known effects on pregnancy or lactation?
  Safety data in pregnant women are limited. Animal studies have not shown teratogenicity, but the drug is classified as Category C; it should be used only if the potential benefit justifies the risk. Breastfeeding is not recommended while on therapy.

Glossary

NS5B polymerase inhibitor

A class of antiviral drugs that block the HCV NS5B RNA‑dependent RNA polymerase, halting viral replication.

Sustained Virologic Response (SVR)

The absence of detectable HCV RNA in blood 12 weeks after completing therapy, considered a cure.

Pan‑genotypic

Active against all major HCV genotypes (1‑6) without the need for genotype‑specific dosing.

Child‑Pugh classification

A scoring system that assesses the severity of chronic liver disease, ranging from class A (mild) to class C (severe).

⚠️ Disclaimer

The information provided about Sofosbuvir is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Sofosbuvir for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.